Introduction
Kainate receptors are a subtype of ionotropic glutamate receptors abundantly expressed in the hippocampus, but their physiological function is only now beginning to emerge [1] . The over-stimulation of kainate receptors leads to epileptiform activity and has proven to be a valuable experimental animal model of temporal lobe epilepsy [2] . One proposed mechanism of kainate-induced epileptogenesis is the disruption of GABAergic transmission [1] , which was found in electrophysiological recordings of hippocampal synaptic transmission to involve a metabotropic action of kainate receptors [3] . However, electrophysiological approaches have not unambiguously resolved if kainate receptors presynaptically inhibit GABA release [4] or if dendritic kainate receptors cause a sustained depolarization of GABAergic interneurons indirectly decreasing evoked GABAergic transmission [5] . In such situations where both somatic and presynaptic receptors contribute to a response, electrophysiological approaches have to rely on miniature potential analysis to indirectly study the mechanisms of presynaptic inhibition. However, there are previous examples of presynaptic modulators, such as adenosine, that a¡ect spontaneous and evoked release of neurotransmitters via di¡erent mechanisms (discussed in [6] ). An alternative is to use an experimental model ideally suited to study the presynaptic modulation of neurotransmitter release, the synaptosomes [7] . Thus, we now directly tested if kainate receptor inhibition of GABA release from hippocampal synaptosomes [8] depends on protein G activation and on protein kinase activities, with care to distinguish if the protein kinases participated on the kainate receptor transducing pathway or were modulating kainate receptor function.
Materials and methods
Domoic acid, phorbol-12,13-didecanoate and 4K-phorbol-12,13-didecanoate were from RBI, ( After loading, the synaptosomes were washed in gassed Krebs solution containing nipecotic acid (1 WM), which was present in all superfusion solutions. The synaptosomes were then layered over Whatman GF/C ¢lters in 90 Wl chambers and superfused with gassed Krebs solution with a £ow rate of 0.6 ml/min. After 45-min washing, e¥uent samples were collected in 3-min fractions and 500 Wl were used for scintillation counting. The synaptosomes were stimulated twice for 2 min with an isomolar substitution of Na by K (20 mM) 4 min (S 1 ) and 22 min (S 2 ) after starting sample collection. Under these conditions, K -evoked tritium release is mostly Ca 2 -dependent and is mainly due to [ 3 H]GABA release [8] , allowing measurement of the evoked [ 3 H]GABA release as evoked tritium release [8, 9] . The e¡ect of tested drugs, added to the perfusion medium 6 min before S 2 , was evaluated by modi¢cation of tritium release in S 2 /S 1 . When we evaluated the modi¢cations of the e¡ect of domoic acid by other drugs, these drugs were applied 15 min before starting sample collection and hence were present during S 1 and S 2 . When present during S 1 and S 2 , MPPG plus MCPG, CGP 55845 or any of the tested protein kinase modulators (chelerythrine, HA-1004, H-89, KN-62, PD 98059, phorbol-12,13-didecanoate and 4K-phorbol-12,13-didecanoate) did not signi¢cantly alter (P s 0.05) the S 2 /S 1 as compared to the S 2 /S 1 ratio obtained in the absence of drugs (data not shown). When the in£u-ence of pertussis toxin pre-treatment on the e¡ect of tested drugs on [ 3 H]GABA release was investigated, the synaptosomes were treated for 2 h with 2 Wg/ml of activated pertussis toxin at 37³C (see [10] ), before labelling with synaptosomal membranes, as described in [10] . Before preparation of the membranes, the synaptosomes were incubated for 15 min at 37³C without or with either the protein kinase A activator, 8-bromo-cAMP (1 mM), or with the protein kinase C activator, phorbol-12,13-didecanoate (250 nM), as described [11] . The values are presented as mean þ S.E.M. To test the signi¢cance of the e¡ect of a drug versus control, a paired Student's t-test was used. When making comparisons from a di¡erent set of experiments with control, one way analysis of variance (ANOVA) was used, followed by Dunnett's test. P90.05 was considered to represent a signi¢cant di¡erence.
Results and discussion
Since hippocampal kainate receptors can couple to G i /G o proteins [10] and pertussis toxin (PTx) attenuates kainate receptor-mediated inhibition of GABAergic transmission [3] , we now tested the e¡ect of PTx pre-treatment directly on [ 3 H]GABA release from superfused hippocampal synaptosomes. Pre-treatment of the synaptosomes with PTx (2 Wg/ ml) for 2 h at 37³C did not change the loading with [ 3 H]GABA and the basal and evoked release of tritium (see Fig. 1 ). To test the e¡ectiveness of this PTx pre-treatment to inactivate G i /G o proteins, we ¢rst tested the e¡ect of PTx treatment on the inhibitory e¡ect of GABA B receptors that are coupled to G i /G o proteins in hippocampal GABAergic nerve terminals [12] . The GABA receptor agonist, muscimol (10 WM), inhibited the evoked release of [ 3 H]GABA by 34 þ 4% (n = 4) from control synaptosomes (Fig. 1A) and this e¡ect was fully prevented by CGP 55485 (1 WM, present during S 1 and S 2 , n = 3, Fig. 1B) indicating the involvement of GABA B receptors. In PTx-treated synaptosomes (Fig. 1B) , the inhibitory e¡ect of muscimol (10 WM) was attenuated by 81 þ 6% (n = 4) compared to control synaptosomes, con¢rming that PTx treatment attenuates responses involving G i /G o proteins. The kainate receptor agonist, domoate (3 WM) caused a 24 þ 3% inhibition (n = 4) of the evoked release of [ 3 H]GABA from control synaptosomes (Fig. 1C) , an e¡ect previously shown to be antagonized by the non-NMDA ionotropic glutamate receptor antagonist, CNQX (10 WM) and by the GluR6 antagonist, NS-102 (1 WM), i.e. involving the activation of pharmacologically de¢ned kainate receptors, possibly of the GluR6 subtype [8] . In PTx-treated synaptosomes, domoate only caused a 6 þ 1% inhibition of the evoked release of [ 3 H]GABA (n = 4) (Fig. 1D) (Fig. 1D) .
One aspect that remained to be ruled out was the possible direct activation of metabotropic glutamate receptors by domoic acid. The simultaneous presence of the group I and II antagonist, (S)-K-methyl-4-carboxyphenylglycine (500 WM), Fig. 1 . Inhibition by the GABA B receptor agonist, muscimol, and by the kainate receptor agonist, domoate, of GABA release from rat hippocampal synaptosomes is sensitive to pertussis toxin. In (A) and (C) the time course of [ 3 H]GABA release is shown. The preparation was challenged with two periods of stimulation with 20 mM K (S 1 and S 2 ), as indicated by the bars above the abscissa. The open symbols represent tritium release from a control chamber, to which no drug was added, and the ¢lled symbols represent the tritium release of the test chamber, to which either muscimol (10 WM; in A) or domoate (3 WM; in C) was added through the superfusate, as indicated by the upper bar. In (B) and (D) it is shown that pre-treatment of the synaptosomes with activated pertussis toxin (2 Wg/ml) attenuated the inhibitory e¡ect of muscimol (10 WM; in B) and of domoate (3 WM; in D). The results are mean þ S.E.M. of four experiments. *P 6 0.05 versus the inhibitory e¡ect of muscimol (10 WM; in B) or of domoate (3 WM; in C) in control synaptosomes (¢rst column). and of the group II and III antagonist, (RS)-K-methyl-4-phosphonophenylglycine (1 mM), did not attenuate the domoate (3 WM)-induced inhibition of [ 3 H]GABA evoked release, which was 21 þ 2% in the absence and 26 þ 4% in the presence of the metabotropic receptor antagonists (n = 3). Thus, it is unlikely that metabotropic glutamate receptor activation may be responsible for the domoic acid induced inhibition of
The triggering of a metabotropic action by kainate receptor activation to inhibit [ 3 H]GABA evoked release was further investigated by testing the e¡ect of protein kinase inhibition on kainate receptor-mediated inhibition of [ 3 H]GABA evoked release. As illustrated in Fig. 2A , the Ca 2 -calmodulin kinase II inhibitor KN-62 (1 WM, n = 3) or the mitogen-activated protein kinase kinase inhibitor PD 98059 (50 WM, n = 3) failed to signi¢cantly (P s 0.05) modify the domoate (3 WM)-induced inhibition of [ 3 H]GABA evoked release ( Fig. 2A) , suggesting a lack of direct involvement of these two transducing systems. In contrast, the inhibition by domoate (3 WM) of [ 3 H]GABAevoked release was attenuated by 82 þ 8% by the protein kinase C inhibitor, chelerythrine (6 WM, n = 4) (Fig. 2B) . Furthermore, supramaximal activation of hippocampal protein kinase C activity with 250 nM phorbol-12,13-didecanoate (see [11] ) also prevented the domoate induced GABA inhibition (n = 3) (Fig. 2B) , whereas its inactive analogue, 4K-phorbol-12,13-didecanoate (250 nM, n = 2) was devoid of e¡ects (Fig. 2B) . This con¢rms the previous suggestion of the involvement of protein kinase C on the presynaptic modulation of GABA release (see [3] ). The inhibition by domoate (3 WM) of [
3 H]GABA evoked release was also inhibited by 26 þ 4% by the protein kinase A inhibitor HA-1004 (10 WM, n = 4) ( Fig.  2A) . However, the more selective protein kinase A inhibitor, H-89 (1 WM, n = 2, or 3 WM, n = 2) did not modify the domoate (3 WM)-induced inhibition of GABA release ( Fig. 2A) . This suggests that the protein kinase A pathway is not recruited by kainate receptors, as reported by others [3] , and the e¡ect of HA-1004 might be due to its ability to inhibit protein kinase C due to its low protein kinase A versus C selectivity [13] .
Kainate receptor function has previously been shown to be controlled by protein kinases, namely by protein kinase A (e.g. [14] ). Therefore, it is important to distinguish if protein kinases are triggered by kainate receptor activation or if protein kinases are controlling kainate receptor function. To investigate this issue, we tested the ability of the membranepermeable protein kinase A activator, 8-bromo-cAMP (1 mM) and of the protein kinase C activator phorbol-12,13-didecanoate (250 nM) to modify binding to kainate receptors. The pre-treatment of hippocampal synaptosomes for 15 min with the protein kinase C activator failed to signi¢-cantly (P s 0.05) modify [
3 H]MGA saturation curve to membranes prepared from these synaptosomes when compared to control (Fig. 2B ), which contrasts with the reduction in K D caused by PTx [10] . However, activation of protein kinase A lead to a reduction in the binding of the higher concentrations of [ 3 H]MGA (Fig. 2B) , although the changes in K D and B MAX did not reach statistical signi¢cance (P s 0.05). Thus, the present results support the view that protein kinase C may be part of the transducing pathway of kainate receptor-mediated inhibition of GABA release rather than directly regulating kainate receptor function. In contrast, protein kinase A is not part of the transducing system operated by kainate recep- Fig. 2 . Ability of inhibitors and activators of protein kinases to affect the kainate receptor-mediated inhibition of GABA evoked release from rat hippocampal nerve terminals (A and B) and [ 3 H]MGA-binding to rat hippocampal synaptosomal membranes (C). In (A) and (B), the protein kinase inhibitors were added 15 min before starting sample collection, i.e. they were present both during S 1 and S 2 , whereas domoate was added 6 min before S 2 onwards. The results are mean þ S.E.M. of 3^4 experiments, except for 4K-phorbol-12,13-didecanoate which is n = 2. *P 6 0.05 versus 0%; **P 6 0.05 versus the inhibitory e¡ect of domoate (3 WM) (¢rst column). In (C) the average saturation curves are shown of [ 3 H]MGAbinding to rat hippocampal synaptosomal membranes upon pretreatment of the synaptosomes in the absence of drugs (circles) or in the presence of the protein kinase A activator, 8-bromo-cAMP (1 mM, ¢lled squares), or of the protein kinase C activator, phorbol-12,13-didecanoate (250 nM, black and white arrowheads) for 15 min at 37³C. The ordinates represent the speci¢c binding of tors to inhibit GABA release but may directly regulate kainate receptor function in the hippocampus.
The present results demonstrate that kainate receptor activation requires functional G i /G o proteins to inhibit GABA release from hippocampal nerve terminals, con¢rming previous electrophysiological data indicating a PTx-sensitive kainate receptor inhibition of GABAergic transmission in hippocampal CA1 area [3] . The qualitative similarity of PTx sensitivity of this direct presynaptic e¡ect of kainate receptor activation on GABA release and on GABAergic transmission is suggestive of a main presynaptic locus of kainate receptor action in the control of GABAergic function in the hippocampus. Like presynaptic kainate receptors, postsynaptic AMPA receptors can also signal through G proteins (e.g. [15] ). However, it is still not clear if these ionotropic glutamate receptors directly couple to G i /G o proteins or more likely indirectly couple to G proteins via ancillary proteins (e.g. [16] ). Also, the metabolic route operated by presynaptic kainate receptors downstream of G i /G o proteins remains to be determined, but appears to be di¡erent from that triggered by postsynaptic AMPA receptors (see [15] ).
